Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19 CAR-T cells (National Taiwan University Hospital)
- Development stage
- Unknown
- Lead developer
- National Taiwan University Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD19 Chimeric Antigen Receptor (CAR) T cells developed by National Taiwan University Hospital (NTUH) is an autologous cell therapy designed for the treatment of B-cell malignancies. The therapy involves the genetic modification of a patient's own T cells to express a chimeric antigen receptor that specifically targets the CD19 antigen, a protein widely expressed on the surface of both normal and malignant B cells. The manufacturing process utilizes the Miltenyi Biotec CliniMACS Prodigy system, an automated platform for cell processing and expansion. Following a lymphodepletion chemotherapy regimen, the modified T cells are infused back into the patient, where they recognize and eliminate CD19-positive tumor cells through cell-mediated cytotoxicity. It is currently being evaluated in a Phase I clinical trial for children and adults with relapsed or refractory B-cell malignancies, including acute lymphoblastic leukemia and non-Hodgkin lymphoma.
- Other names
- CD19 Chimeric Antigen Receptor (CAR) T CellsAutologous CD19 CAR T cells
02
Targets
Beyond the preview
Go deeper on CD19 CAR-T cells (National Taiwan University Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19 CAR-T cells (National Taiwan University Hospital).